12 results about "Antimalarial Agent" patented technology

Methods of treating malaria comprising administration of compounds of Formula (I′) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

Provided are methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Also provided are uses of the compounds of Formula (I), as defined herein, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

The present invention provides methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for the possible inhibition of plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

The present invention is related to new compounds useful in the manufacture of a medicament for preventing or treating malaria, pharmaceutical compositions, methods of preparation and uses thereof.

The present disclosure generally relates to substituted heteroaromatic compounds. The invention relates to novel substituted 4-heteroatom-isoquinolone compounds, and isomers, derivatives, analogues and / or salt forms thereof of formula I; and its process of preparation thereof. Furtherore, the present invention relates to a process of preparation of various drugs / APIs / alkaloids e.g. Ampikin APIs such as CX-614, CX-554, DRF-2655, ITF-296, ITF-1129, Raititrexed, Deoxyvasicinone family of quinazolinone alkaloids, etc. using said formula I compound as starting material. The compound of formula I acts as antimalarial agent, anticancer agent, neuroprotective agent and so on. Formula I

The present invention discloses a functionalized isoquinolone and quinolone compounds and an efficient transition-metal-free approach for the synthesis of the same. The invention provides a highly functionalized isoquinolones from the reaction of dimethyl-2-((phenylamino)methylene) malonate with aryne precursors under mild. The reaction proceeds through insertion of aryne into the C−C σ-bond, which offers a novel and practical entry to access a wide range of isoquinolones with enhanced yields. The substrate scope is broad as the process can stands a variety of functional groups and the application of the developed process has been demonstrated in the total synthesis of antimalarial agent SJ000101247. Also, the highly functionalized quinolones are also useful in the synthesis of floxacins based compounds and derivatives e.g. ciprofloxacin, norfloxacin, G003967, etc.

Among the various aspects of the present disclosure is the provision of methods of suppressing Plasmodium parasite growth or infectivity or treating malaria comprising administering a polybasic antimalarial agent. The polybasic peptides and polymers provided can be used for the treatment of Plasmodium falciparum and other plasmodium species that cause human malaria.

Malaria still afflicts about half of the world population causing more than 400,000 deaths, mostly children. The options for malaria therapy are increasingly becoming limited because of widespread drug resistance. Furthermore, drugs for prophylaxis are suboptimal. This disclosure reports the identification of type II protein kinase inhibitor compounds which have never been explored as antimalarial agents and which now have been discovered to possess therapeutic and prophylactic properties against malaria.

Provided are methods of treating malaria comprising administration of compounds of Formula (I), or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Also provided are uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

Disclosed are compounds of Formula (I): # imgabs0 # wherein R1, R2, R3, A and B are as defined herein, as well as methods of making such compounds. Also disclosed are pharmaceutical compositions comprising the compounds of Formula (I), methods of blocking the transmission of Plasmodium parasites, and methods of treating or preventing malaria by killing or blocking the growth of a Plasmodium organism in a mammal, where the Plasmodium organism is in the hepatic phase, asexual phase or is a gametoblastic cell, the methods comprise administering to the animal an effective amount of a compound of formula (I).

This invention provides methods for treating acute respiratory distress syndrome (ARDS), including ARDS associated with respiratory viral infections. [Solution] Administer plasma kallikrein (pKal) inhibitors such as anti-pKal antibodies as inhibitors of the contact activation pathway. Immunomodulators such as IL-6R inhibitors, antiviral agents such as lopinavir, ritonavir, interferon beta, umfenovir, and remdesivir, antimalarial agents such as chloroquine, and / or inhibitors of the contact activation pathway such as C1 inhibitors, pKal inhibitors, and bradykinin receptor antagonists may be administered to the patient as additional therapeutic agents.